Objectiu de la convocatòria

IMI is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA).
The goal of the Innovative Medicines Initiative 2 (IMI 2) is to develop next generation vaccines, medicines and treatments, such as new antibiotics. It will build on the successes and lessons learnt under IMI. Like IMI, it will bring together companies, universities, public laboratories, innovative small and medium-sized enterprises (SMEs), patient groups and regulators in collaborative projects that will pave the way for breakthrough vaccines, medicines and treatments to tackle Europe's growing health challenges, and secure the future international competitiveness of Europe's pharmaceutical industry.

Característiques principals

IMI2 – Call 18 is a standard two-stage Call for proposals with the following topics:

-Topic 1: Central repository of digital pathology slides to support the development of artificial intelligence tools

-Topic 2: Health Outcomes Observatories – empower patients with tools to measure their outcomes in a standardised manner creating transparency of health outcomes

-Topic 3: Improving patient access, understanding and adherence to healthcare information: an integrated digital health information project

-Topic 4: Establishing international standards in the analysis of patient reported outcomes and health-related quality of life data in cancer clinical trials

-Topic 5: Accelerating research & innovation for advanced therapy medicinal products

-Topic 6: Supporting the development of engineered T cells

IMI2 - Call19 is a single stage restricted Call for proposals designed to support further research activities to allow existing successful IMI consortia to build on the achievements of their initial action, move onto the next step of the research challenge, and maximise the impacts of the initial action results. As such the Call is restricted to the initial consortia of actions that fulfil the following two conditions:

- derived from topics where the topic text already informed potential applicants about the possibility of a later restricted Call.

In practice, the consortia that meet these criteria are: ADAPT-SMART, BEAt-DKD, DO-IT, HARMONY, INNODIA, ITCC-P4, MOPEAD, NGN-PET, PRISM, RADAR-CNS, RESCEU, RHAPSODY, TransQST.

Característiques principals

Call 18 is being run in a two-stage submission and evaluation process.

- Stage 1 submission deadline:  26 September 2019 (17:00:00 Brussels time)

- Stage 2 submission deadline: 26 March 2020 (17:00:00 Brussels time)

Call 19 is being run in a single-stage submission and evaluation process.

- Single stage submission deadline: 26 September 2019 (17:00:00 Brussels time)

Dotació

IMI JU collaborative projects are implemented through a co-financing scheme. The IMI JU grants financial support to the eligible entities, while the other entities (including the EFPIA companies) participate in the project with their own resources.

Call 18:

-Topic 1: 35 million euros

-Topic 2: 11.4 million euros

-Topic 3: 9.3 million euros

-Topic 4: 3.2 million euros

-Topic 5: 13 million euros

-Topic 6: 8.7 million euros

Call 19:

Applicant consortia will be competing for a maximum of 20 million euros

Durada

Call 18 - the indicative duration of the action is:

- Topic 1- 72 months

- Topic 2- 60 months

- Topic 3- 60 months

- Topic 4- 48 months

- Topic 5- 60 months

- Topic 6- 60 months

Call 19 - the indicative duration of the action is 24 months

Convocatòria (URL)

https://www.imi.europa.eu/apply-funding/open-calls/imi2-call-18

https://www.imi.europa.eu/apply-funding/open-calls/imi2-call-19